FDA Approves First Therapy for Friedreich's Ataxia

Just in time for Rare Disease Day, patients with a rare neuromuscular disorder got their first medicine as the FDA approved Reata Pharmaceuticals’ omaveloxolone.

Two weeks of tension and market swings culminated in a win for Reata, as the FDA greenlit omaveloxolone to treat Friedreich’s ataxia nearly two hours after the market closed Tuesday. The drug, which will be marketed as Skyclarys, is approved to treat adults and teenagers 16 and older.